Methods of treating an inflammatory-related disease

• US 7,582,670 B2
• Filed: 04/13/2005
• Issued: 09/01/2009
• Est. Priority Date: 12/13/2001
• Status: Expired due to Term

• Current Assignee: Natrogen Therapeutics International, Inc.
• Original Assignee: Natrogen Therapeutics, Inc.
• Inventors: McCarron, James P. Jr., Mo, Lian, Liu, Xiao Mei, Mencher, Simon K., Wang, Longgui
• Primary Examiner(s): Marschel; Ardin
• Assistant Examiner(s): JAGOE, DONNA A
• Application Number:
  US11/104,422
• Publication Number:
  US 20050197381A1
• Time in Patent Office: 1,602 Days
• Field of Search: 514/254.09, 514/414, 514/415, 514/416, 514/171, 514/570, 514/159
• US Class Current: 514/414
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/404 Indoles, e.g. pindolol
• CPC Class Codes: A61K 31/606 having amino groups
• CPC Class Codes: A61K 31/7056 containing five-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: A61K 45/00 Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

Claims

1. A method of treating ulcerative colitis, which comprises administering to an animal in need of such treatment a compound of formula (IV)

2. The method according to claim 1, wherein the animal is a human being.

3. The method according to claim 1, wherein the compound is administered at a concentration sufficient to inhibit cytokine IL-1α

, β

, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-α

, LT, LIF, Oncostatin, or IFNc1α

, β

, γ

.

4. The method according to claim 1, where the compound is administered at a concentration sufficient to stimulate expression of cytokine IL-4, IL-10, IL-11, W-13 or TGFβ

.

5. A method of treating ulcerative colitis, the method comprising administering to an animal in need of such treatment a compound of formula (IV)

6. The method according to claim 5, wherein the compound is administered at a concentration sufficient to inhibit cytokine IL-1α

, β

, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-α

, LT, LIF, Oncostatin, or IFNc1α

, β

, γ

.

7. The method according to claim 5, where the compound is administered at a concentration sufficient to stimulate expression of cytokine IL-4, IL-10, IL-11, W-13 or TGFβ

.